FBXO5驱动肝细胞癌的进展,是茶叶多中介抑制的目标
Xinyu Wang1, Dandan Yang1, Jiao Wang1
1Bengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China.
在肝细胞癌 (HCC) 中,FBXO5作为瘤基因起作用. 茶叶多醇 (TPs) 通过降低FBXO5的调节来抑制HCC的进展,这表明TPs是治疗HCC的潜在治疗剂.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 自然产品化学 自然产品化学
背景情况:
- 肝细胞癌 (HCC) 是全球主要的癌症,治疗选择有限.
- FBXO5被认为是各种癌症的瘤基因,但其在HCC中的作用尚未完全理解.
- 茶叶多 (TPs) 具有抗瘤特性,但它们在HCC中的特定分子标仍然难以捉摸.
研究的目的:
- 调查FBXO5在HCC病变发生中的作用.
- 通过针对FBXO5.5来确定TP是否在HCC中发挥其抗瘤作用.
主要方法:
- 使用癌症基因组图谱 (TCGA) 数据分析了HCC中的FBXO5表达.
- 在HCC细胞系中利用siRNA敲除和过度表达来评估FBXO5功能.
- 评估了TP对HCC细胞活力,增殖,迁移和入侵的影响,通过RT-qPCR和西白斑测量FBXO5表达.
主要成果:
- FBXO5在HCC中显著上调,并与预后不佳有关.
- FBXO5的淘汰抑制了HCC细胞的增殖和迁移;过度表达促进了这些行为.
- TPs以剂量依赖的方式抑制了HCC细胞的活力和运动性,降低了FBXO5表达的调节.
结论:
- 在HCC中,FBXO5作为瘤基因起作用.
- 通过向和抑制FBXO5,TP显示出作为HCC治疗剂的潜力,从而抑制瘤进展.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
